


# renibus therapeutics

**PREVENT. PROTECT. IMPROVE.**

We are Dedicated to Transforming the Cardio,  
Renal and Metabolic Diseases Treatment Paradigm



## About Us

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases.

Renibus' first-in-a-new-class lead program is RBT-1, which is in a Phase 3 pivotal trial to show a reduction in post-operative complications and improve outcomes following cardiac surgery. The drug has received FDA Breakthrough and Fast Track Designations.


Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are targeting several indications where Veverimer's mechanism of action as a hydrochloric acid binder within the gastrointestinal tract may provide benefit in treating orphan diseases with an unmet medical need.

Renibus has three additional assets at earlier stages of development.

## Quick Facts:

Founded in 2016 and  
Headquartered in Southlake, TX

Robust pipeline of programs to prevent disease progression, improve outcomes and protect against organ damage in cardio, renal and metabolic diseases.



## Leadership Team

D. Jeff Keyser, RPh, JD, PhD, *President & Chief Executive Officer*  
Bhupinder Singh, MD, *Chief Medical Officer*  
Jamie A. Donadio, *Chief Financial Officer*  
Asha Ramdas, *Chief Technical Officer*

## Board of Directors

Henrik Rasmussen, MD, PhD, *Chairman*  
D. Jeff Keyser, RPh, JD, PhD, *President & Chief Executive Officer*  
Bhupinder Singh, MD, *Director*  
Carlos Guillem, MBA, PhD, *Director*

We have developed a robust portfolio of products that act by activating multiple cytoprotective pathways.

Program	Indication/Condition	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights
<b>RBT-1</b> Stannic protoporphin/iron sucrose	Reducing the risk of post op complications in cardiothoracic surgery					
<b>Veverimer (Alezuris™)</b>	Undisclosed					
<b>Additional Programs</b>	Undisclosed					

## Our patients are the core of what we do.

We'd like to express our appreciation for the patients who have previously participated or are currently enrolled in our clinical trials. Your contributions will help others as a result of the knowledge gained from your participation.



RBT-1 Pivotal  
Phase 3 Study  
**Now Enrolling**



Learn more at  
[renibus.com/patients](https://renibus.com/patients)



To learn more about Renibus visit [renibus.com](https://renibus.com) or scan the QR code to the right.

